Health professionals reportedly are receiving letters this week alerting them to an FDA warning just issued about risks of thyroid cancer and pancreatitis associated with the popular type 2 diabetes drug liraglutide (Victoza). Yikes!

According to MSM reports, the evidence was found in mice, and it's unclear if the serious risks translate to humans — but there was enough concern to issue the follow warning:

"Clinical trials have shown more cases of pancreatitis with liraglutide than with other diabetes drugs, so the FDA recommended patient monitoring after starting liraglutide or raising the dosage, for symptoms such as persistent severe abdominal pain. This pain can sometimes radiate to the back and is accompanied by vomiting.

Liraglutide should be immediately stopped if pancreatitis is suspected and not restarted if the disease is confirmed.

The FDA urged a cautious approach in patients with a history of pancreatitis. The agency also highlighted the contraindication for liraglutide in patients with a personal or family history of medullary thyroid cancer or a personal history of multiple endocrine neoplasia syndrome type 2."

Seeing as how the 'Mine has become home to the unofficial leading chat forum for Victoza users, we thought you all might like to know! We'll be posting an alert there as well, of course.

Disclaimer: Content created by the Diabetes Mine team. For more details click here.

Disclaimer

This content is created for Diabetes Mine, a consumer health blog focused on the diabetes community. The content is not medically reviewed and doesn't adhere to Healthline's editorial guidelines. For more information about Healthline's partnership with Diabetes Mine, please click here.